MicroPort® Receives Approval to Launch ARBORES™ Kyphoplastic Balloon Catheter in China

Shanghai, China – Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort”) announced that its independently developed ARBORES™ Kyphoplastic Balloon Catheter (“ARBORES™”) was granted registration certificate from National Medical Products Administration of China (NMPA) recently.

As a core product for percutaneous kyphoplasty, ARBORES™ is used for the reduction of fractures and/or creation of a void in cancellous bone in the spine, along with the accessories such as balloon pump, puncture needle and dilator. The ARBORES™ approved by NMPA has six specifications, with the balloons ranging in length from 10mm to 20mm and featuring excellent crossability after being folded. The balloon dilation also demonstrates good support performance.

Previously, ARBORES™ was granted the CE Mark and entered the European Union market in 2017. The MicroPort product of Percutaneous Vertebroplasty Guided System, which is used in combination with ARBORES™, was also approved to launch in China in 2018. After the NMPA approval for ARBORES™, the balloon catheter product line of MicroPort has been significantly reinforced. Meanwhile, MicroPort is able to provide the doctors and patients with more comprehensive therapeutic solutions in the field of osteoporotic vertebral compression fracture.